S

Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399

Watchlist Manager
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
Watchlist
Price: 11.07 CNY 1.84% Market Closed
Market Cap: 13.8B CNY
Have any thoughts about
Shenzhen Hepalink Pharmaceutical Group Co Ltd?
Write Note

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
S
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
Capital Expenditures
-ÂĄ310.3m
CAGR 3-Years
-17%
CAGR 5-Years
8%
CAGR 10-Years
-6%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Capital Expenditures
-ÂĄ219.6m
CAGR 3-Years
46%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Capital Expenditures
-ÂĄ103.9m
CAGR 3-Years
37%
CAGR 5-Years
-6%
CAGR 10-Years
4%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Capital Expenditures
-ÂĄ1.6B
CAGR 3-Years
-3%
CAGR 5-Years
-27%
CAGR 10-Years
-23%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Capital Expenditures
-ÂĄ548.5m
CAGR 3-Years
1%
CAGR 5-Years
6%
CAGR 10-Years
-27%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Capital Expenditures
-ÂĄ81.9m
CAGR 3-Years
-75%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Glance View

Market Cap
13.8B CNY
Industry
Pharmaceuticals

Shenzhen Hepalink Pharmaceutical Group Co Ltd is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Shenzhen, Guangdong and currently employs 2,046 full-time employees. The company went IPO on 2010-05-06. Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based pharmaceutical company focused on the field of heparin sodium preparations and raw materials, macromolecular drugs contract development manufacturing organization (CDMO) and innovative drug development. The Company’s main products and services include enoxaparin sodium preparations and heparin sodium bulk medicines, enoxaparin sodium bulk medicines, and CDMO services for macromolecular drugs. The firm distributes its products within the domestic market and to overseas markets, including Turkey, Brazil, the United States and others.

Intrinsic Value
12.97 CNY
Undervaluation 15%
Intrinsic Value
Price
S

See Also

What is Shenzhen Hepalink Pharmaceutical Group Co Ltd's Capital Expenditures?
Capital Expenditures
-310.3m CNY

Based on the financial report for Sep 30, 2024, Shenzhen Hepalink Pharmaceutical Group Co Ltd's Capital Expenditures amounts to -310.3m CNY.

What is Shenzhen Hepalink Pharmaceutical Group Co Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-6%

Over the last year, the Capital Expenditures growth was 7%. The average annual Capital Expenditures growth rates for Shenzhen Hepalink Pharmaceutical Group Co Ltd have been -17% over the past three years , 8% over the past five years , and -6% over the past ten years .

Back to Top